Financial Data and Key Metrics Changes - As of September 30, 2020, cash and cash equivalents totaled $23.1 million, an increase of $11.2 million from $11.9 million as of December 31, 2019, primarily due to net proceeds of $18.3 million from an equity financing in April 2020, offset by net cash used in operating activities of $6.8 million [30] - The net loss for the three months ended September 30, 2020, was $2.3 million compared to $1.9 million for the same period in 2019 [34] Business Line Data and Key Metrics Changes - Research and development expenses were $1.1 million for each of the three months ended September 30, 2020, and 2019, with an increase in expenses related to the transcriptional regulation program by almost $0.1 million [31] - General and administrative expenses for the three months ended September 30, 2020, were $1.5 million, compared to $1.3 million for the same period of the previous year, reflecting an increase of $0.2 million due to increased professional costs [32] Market Data and Key Metrics Changes - The company has opened two Phase 1 dose escalation studies to evaluate the combination of fadraciclib and venetoclax in patients with relapsed or refractory CLL and AML or MDS [18][22] - The anti-mitotic program is evaluating CYC140, a Polo-like kinase 1 inhibitor, with seven patients recruited for the first-in-human study [24] Company Strategy and Development Direction - The company aims to expand the development of oral fadraciclib initially in solid tumors and later in hematological malignancies, responding to clinician requests for oral therapy [17] - The company is focused on demonstrating safety, efficacy, and cost-effectiveness of its medicines to fulfill its strategy and realize stockholder value [49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that cash resources as of September 30 will fund currently planned programs through the end of 2022 [30] - The company plans to report initial data from various studies over the next two years, including the fadraciclib-venetoclax Phase 1 study in relapsed/refractory AML or MDS and CLL [29] Other Important Information - Dr. Mark Kirschbaum was introduced as the new Chief Medical Officer, bringing extensive experience in hematology and oncology [7] - The company is collaborating with The University of Texas MD Anderson Cancer Center for clinical trials, where MD Anderson assumes patient costs for all studies [23] Q&A Session Summary Question: When will the company switch completely to oral fadraciclib if it continues to deliver like intravenous dosing? - Management acknowledged the value of oral therapy and is keen to begin oral evaluation of fadraciclib, with ongoing studies to determine the optimal dosing schedule [35] Question: What proteins are being analyzed in the dose escalation studies? - Management indicated interest in analyzing MCL1, MYC, and cyclin E proteins, with ongoing studies expected to provide more data [40] Question: Are there plans to conduct studies based on recent findings from Duke University regarding CDK2/9 in colorectal cancer? - Management confirmed interest in exploring solid tumors based on preclinical findings but has not yet made decisions regarding specific tumor histologies [42] Question: Any updates on the 160 milligram dose of fadraciclib? - Management clarified that the ongoing Phase 1 study is testing the 160 milligram dose, but the relevance of this dose may change as the program progresses towards oral formulations [44]

Translating cancer biology into medicines October 2020 Disclaimer This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward- looking statements and forecasts involve risks and uncertainties because they relate to events and depend on ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number 000-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specifi ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2020 Earnings Conference Call August 12, 2020 4:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance & Chief Operating Officer Judy Chiao - Vice President of Clinical Development & Regulatory Affairs Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Kumar Raja - Brooklyn Capital Markets Wangzhi Li - Ladenburg Operator Good after ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2020 Results Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Judy Chiao - Vice President of Clinical Development and Regulatory Affairs Conference Call Participants Jonathan Aschoff - Roth Capital Partners Wangzhi Li - Ladenburg Kumar Raja - Brooklyn Capital Markets Operator G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ | --- | --- | |-------------------------------------------------------------------------|-------------------------| | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 00‑50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 91‑1707622 (State or Other Jurisdiction of Incorp ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2019 Results Conference Call February 26, 2020 4:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Dr. Judy Chiao - Vice President of Clinical Development and Regulatory Affairs Conference Call Participants Wangzhi Li - Ladenburg Thalmann Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Fourth Quar ...

Translating cancer biology into medicines NASDAQ CYCC – BIOCEO Conference February 10, 2020 Disclaimer | --- | --- | |-------------------------------------------------------------------------------------|---------------| | | | | This presentation contains forward-looking statements | within the | | meaning of the "safe harbor" provisions of the Private Securities | Litigation | | Reform Act of 1995 about financial results and estimates, | business | | strategy, clinical trial plans and research and developm ...

Translating cancer biology into medicines NASDAQ CYCC Biotech Showcase - January 13, 2020 Disclaimer | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------| | | | | This presentation contains forward-looking statements within | the meaning | | of the "safe harbor" provisions of the Private Securities | Litigation Reform | | Act of 1995 about financi ...